Clinical Trials
First Patient in Europe Receives Implant of GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System and Enrolls in Post-Market Registry
Investigator initiated EXCeL Registry will assess safety and abdominal aortic aneurysm treatment success in patients with challenging anatomies 17/09/2018 — FLAGSTAFF, Ariz. — (BUSINESS WIRE) W. L. Gore & Associates, […]
BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
Regulatory Approvals In-Process; New Record Date to be Set Shortly 17/09/2018 — ALAMEDA, Calif. — (BUSINESS WIRE) BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, […]
CorFlow Completes USD 9.7M in Seed Funding
14/09/2018 — BAAR, Switzerland — (BUSINESS WIRE) CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company has completed the 2nd close of its Seed+ financing round. To date, and since the CorFlow […]
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an undisclosed target The collaboration will investigate a new therapeutic approach that […]
Phase III Study using 22nd Century’s SPECTRUM® Research Cigarettes Demonstrates Immediate Reduction to Very Low Nicotine is Most Likely to Lead to Less Harm
“Minimally or non-addictive Very Low Nicotine cigarettes are the ultimate harm reduction strategy” 06/10/2017 — CLARENCE, N.Y. — (BUSINESS WIRE) 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology […]
Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research
Helps companies accelerate the development of new medications by reducing the failure rate during the clinical phase 21/06/2017 — STRASBOURG, France — (BUSINESS WIRE) Bionext, a bioinformatics company, announces today […]
Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke
Studies conducted to date clearly indicate that IQOS is likely to present less risk of harm compared to smoking 27/03/2017 — LAUSANNE, Switzerland — (BUSINESS WIRE) Philip Morris International Inc. […]
LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
06/01/2017 — LES ULIS, France — (BUSINESS WIRE) LFB S.A., announced that its Biologic License Application (BLA), requesting marketing approval of Coagulation Factor VIIa (Recombinant) as a treatment for congenital […]
ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations
Interim study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in the pivotal Phase III trial 06/12/2016 — […]
Senseonics Reports Topline Accuracy Results from U.S. Pivotal Study of Eversense CGM System.
Topline Accuracy of 8.8% MARD (Mean Absolute Relative Difference) over 90 Days. 09/08/2016 — GERMANTOWN, Md. — (BUSINESS WIRE) Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development […]